lifestyle.buyersdesire.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Amneal Pharmaceuticals LLC
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
April 14, 2026
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
April 9, 2026
Amneal to Report First Quarter 2026 Results on May 1, 2026
April 7, 2026
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
April 7, 2026
Amneal to Participate in Upcoming Investor Conference
March 13, 2026
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
January 28, 2026
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
January 27, 2026